RecruitingNCT06561399

Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

Studying Leukoencephalopathy with calcifications and cysts

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fujian Provincial Hospital
Principal Investigator
Shao-Ming Wei
Fujian Provincial Hospital
Intervention
TACE, Lenvatinib combination with Sintilimab sequential radiotherapy(combination_product)
Enrollment
28 target
Eligibility
18-75 years · All sexes
Timeline
20242028

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06561399 on ClinicalTrials.gov

Other trials for Leukoencephalopathy with calcifications and cysts

Additional recruiting or active studies for the same condition.

See all trials for Leukoencephalopathy with calcifications and cysts

← Back to all trials